Sectors & IndustriesHealthcareBiotechnology
Best Biotech Stocks to Buy Now (2026)
Top biotech stocks in 2026 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best biotech stocks to buy now. Learn More.

Industry: Biotechnology
F
Biotech is Zen Rated F and is the 137th ranked industry out of 145 stock market industries
Learn how the Zen Ratings work
Ticker
Company
Zen Rating
Financials
Market Cap
ROE
ROA
ROCE
ROIC
D/E
Current Ratio
Gross Margin
Profit Margin
Operating Margin
UNCY
UNICYCIVE THERAPEUTICS INC
$142.92M-184.40%-95.50%-89.14%368.10%0.353.83N/AN/AN/A
ARDX
ARDELYX INC
$1.38B-40.60%-13.20%-9.81%-7.80%2.014.3290.30%-15.10%-9.95%
SRZN
SURROZEN INC
$300.26MN/A-236.00%-272.56%-2,341.20%-1.539.22100.00%-6,960.80%-6,960.77%
SEER
SEER INC
$97.33M-26.00%-23.10%-26.18%-25.90%0.1412.8451.10%-444.00%-442.75%
PRLD
PRELUDE THERAPEUTICS INC
$205.39M-130.00%-80.90%-112.65%-138.00%1.061.99100.00%-819.60%-819.59%
PLX
PROTALIX BIOTHERAPEUTICS INC
$174.03M-13.50%-8.30%-7.91%-9.80%0.712.5148.80%-12.50%-8.37%
ABCL
ABCELLERA BIOLOGICS INC
$1.03B-14.80%-10.70%-13.74%-15.00%0.4011.32100.00%-194.90%-236.39%
OABI
OMNIAB INC
$234.55M-24.00%-21.40%-23.29%-87.50%0.134.0298.40%-347.00%-355.16%
CRBU
CARIBOU BIOSCIENCES INC
$181.68M-91.50%-68.50%-99.15%-76.20%0.445.72100.00%-1,327.40%-1,332.33%
TGTX
TG THERAPEUTICS INC
$5.08B101.10%51.90%14.75%15.80%0.644.1083.70%72.60%21.76%
MESO
MESOBLAST LTD
$2.02B-18.20%-13.10%-10.17%-72.20%0.361.5880.50%-144.30%-101.79%
CORT
CORCEPT THERAPEUTICS INC
$4.30B15.10%11.90%6.46%7.60%0.292.9298.30%12.90%5.69%
DMRA
DAMORA THERAPEUTICS INC
$1.51B-307.40%-279.50%-87.24%6,125.20%0.0812.98N/AN/AN/A
BCYC
BICYCLE THERAPEUTICS PLC
$326.23M-33.20%-27.40%-33.09%-530.20%0.1811.98100.00%-301.70%-301.16%
CNTN
CANTON STRATEGIC HOLDINGS INC
$121.61M-588.40%-264.40%-167.25%641.10%0.254.99N/AN/AN/A
PLRZ
POLYRIZON LTD
$13.95M-12.40%-11.70%-18.72%-3,440.00%0.0244.04N/AN/AN/A
MRKR
MARKER THERAPEUTICS INC
$22.34M-80.90%-67.00%-72.51%3,673.90%0.148.39100.00%-343.00%-343.39%
NTHI
NEONC TECHNOLOGIES HOLDINGS INC
$137.88MN/AN/AN/AN/A-1.350.19N/AN/AN/A
RNA
ATRIUM THERAPEUTICS INC
N/AN/A-637.10%148.42%233.10%-1.130.07100.00%-265.90%-266.64%
FHTX
FOGHORN THERAPEUTICS INC
$278.80MN/A-33.50%-53.69%-74.10%-2.832.73100.00%-240.30%-240.33%
CTXR
CITIUS PHARMACEUTICALS INC
$16.11M-52.50%-27.60%-33.67%-48.00%0.590.9980.00%-909.90%-872.34%
GYRE
GYRE THERAPEUTICS INC
$696.20M5.50%3.30%6.48%9.80%0.235.6095.40%4.30%8.22%
CNTB
CONNECT BIOPHARMA HOLDINGS LTD
$187.84MN/AN/AN/AN/A0.225.48N/AN/AN/A
NVAX
NOVAVAX INC
$1.52B-546.20%35.30%64.85%68.30%-10.212.1393.50%39.20%41.36%
CRDF
CARDIFF ONCOLOGY INC
$118.27M-82.00%-64.10%-100.79%-109.80%0.363.67100.00%-7,736.30%-7,732.04%
PRTA
PROTHENA CORP PUBLIC LTD CO
$501.19M-73.00%-62.00%-70.23%3,211.20%0.177.72100.00%-2,520.60%-2,073.82%
BBIO
BRIDGEBIO PHARMA INC
$13.88BN/A-74.40%-103.60%-32.00%-1.442.7795.80%-144.40%-133.72%
LBRX
LB PHARMACEUTICALS INC
$612.49MN/AN/AN/AN/A0.0347.60N/AN/AN/A
URGN
UROGEN PHARMA LTD
$882.12MN/A-72.90%-89.63%-71.90%-2.904.0188.70%-139.80%-125.76%
KLRS
KALARIS THERAPEUTICS INC
$140.21M-73.10%-43.60%-37.49%-426.00%0.5512.23N/AN/AN/A
OVID
OVID THERAPEUTICS INC
$316.50M-24.00%-18.60%-12.21%-22.80%0.168.97100.00%-240.10%-240.13%
ACOG
ALPHA COGNITION INC
$115.67M-52.60%-40.80%-50.11%-1,606.00%0.376.6973.10%-262.20%-266.30%
NXTC
NEXTCURE INC
$36.28M-155.00%-109.20%-140.96%-179.20%0.444.14N/AN/AN/A
PVLA
PALVELLA THERAPEUTICS INC
$1.42B-68.50%-45.50%-49.43%433.60%0.736.49100.00%66,162.30%52,807.55%
VYGR
VOYAGER THERAPEUTICS INC
$240.19M-51.40%-39.40%-52.97%-48.50%0.297.64100.00%-296.50%-296.17%
AKBA
AKEBIA THERAPEUTICS INC
$372.35M-16.70%-1.50%9.58%33.50%10.551.5583.30%-2.30%8.66%
NTLA
INTELLIA THERAPEUTICS INC
$1.57B-56.60%-45.20%-55.90%-54.50%0.255.08100.00%-609.90%-609.85%
AVTX
AVALO THERAPEUTICS INC
$317.90M-77.90%-61.80%-75.44%-143.00%0.408.14100.00%-132,642.40%-132,362.71%
PEPG
PEPGEN INC
$337.28M-75.70%-60.40%-55.57%-114.20%0.1811.94N/AN/AN/A
IVA
INVENTIVA SA
$575.89MN/A-284.90%-93.27%-121.40%-21.092.96100.00%-1,767.30%-638.55%
ZNTL
ZENTALIS PHARMACEUTICALS INC
$184.24M-51.50%-40.00%-51.54%-45.80%0.297.76100.00%368.10%368.64%
ZYME
ZYMEWORKS INC
$1.79B-26.00%-20.60%-26.22%-28.30%0.295.88100.00%-76.60%-75.26%
CANF
CAN-FITE BIOPHARMA LTD
$2.14M-264.10%-129.00%-157.13%1,180.30%0.853.60100.00%-1,571.30%-1,571.25%
FTRE
FORTREA HOLDINGS INC
$882.64M-152.20%-34.60%-49.47%-67.30%3.820.9818.50%-36.20%-32.74%
RANI
RANI THERAPEUTICS HOLDINGS INC
$138.52MN/A-129.00%273.69%-132.60%-2.810.26100.00%-2,359.60%-2,053.83%
SNDX
SYNDAX PHARMACEUTICALS INC
$2.13B-206.60%-49.20%-61.44%-36.70%7.204.4096.00%-165.60%-146.00%
MNKD
MANNKIND CORP
$702.47M-11.20%1.10%6.35%6.50%-16.531.7174.80%1.70%11.30%
NERV
MINERVA NEUROSCIENCES INC
$263.97MN/A-620.10%-306.68%-504.10%-1.6636.28N/AN/AN/A
PRQR
PROQR THERAPEUTICS NV
$166.47M-66.90%-32.10%-50.90%-1,891.60%1.283.09100.00%-258.10%-250.06%
HYFT
MINDWALK HOLDINGS CORP
$56.99M-63.70%-36.50%-67.58%-72.80%0.553.7460.30%-66.50%-65.87%
INO
INOVIO PHARMACEUTICALS INC
$106.40M-353.40%-113.60%-277.23%-1,484.30%2.081.40100.00%-130,000.00%-130,000.00%
IPSC
CENTURY THERAPEUTICS INC
$372.03M-4.90%-3.60%-4.74%-4.80%0.415.97100.00%-8.80%-8.84%
STRO
SUTRO BIOPHARMA INC
$389.25MN/A-79.00%-197.61%-200.30%-2.312.01100.00%-186.50%-190.31%
GRCE
GRACE THERAPEUTICS INC
$72.57M-9.30%-8.60%-10.41%602.20%0.0614.96N/AN/AN/A
LXRX
LEXICON PHARMACEUTICALS INC
$711.78M-41.90%-22.00%-25.59%-30.00%0.724.8899.40%-101.10%-84.34%
SNSE
SENSEI BIOTHERAPEUTICS INC
$37.20M-80.00%-67.50%-104.06%-104.00%0.205.81N/AN/AN/A
COEP
COEPTIS THERAPEUTICS HOLDINGS INC
$69.64M-130.60%-85.20%-82.17%-176.80%0.154.1686.70%-874.30%-867.20%
ALXO
ALX ONCOLOGY HOLDINGS INC
$268.48M-182.00%-113.60%-290.18%-175.40%1.272.07N/AN/AN/A
OKUR
ONKURE THERAPEUTICS INC
$54.69M-81.70%-74.20%-105.90%1,694.40%0.1110.28N/AN/AN/A
ORKA
ORUKA THERAPEUTICS INC
$2.17B-25.30%-24.30%-22.28%-30.30%0.0422.37N/AN/AN/A
ORIC
ORIC PHARMACEUTICALS INC
$1.17B-38.80%-36.20%-33.33%-45.70%0.0614.13N/AN/AN/A
FDMT
4D MOLECULAR THERAPEUTICS INC
$504.39M-31.70%-28.30%-26.80%-34.80%0.129.39100.00%-164.40%-164.43%
NUVB
NUVATION BIO INC
$1.52B-57.50%-35.00%-37.25%-36.30%0.956.9585.20%-325.30%-303.56%
HYPD
HYPERION DEFI INC
$29.96M-123.80%-71.30%-30.02%-78.70%0.172.25-798.10%-7,643.90%-6,846.13%
GPCR
STRUCTURE THERAPEUTICS INC
$3.41B-14.50%-13.80%-9.25%-20.60%0.0524.81N/AN/AN/A
NVO
NOVO NORDISK A S
$162.21B61.10%20.20%39.89%51.50%1.800.8081.00%33.10%42.24%
CMPX
COMPASS THERAPEUTICS INC
$988.68M-43.60%-38.00%-32.34%-49.50%0.1215.02N/AN/AN/A
TRVI
TREVI THERAPEUTICS INC
$1.47B-25.50%-24.20%-23.31%-36.90%0.0619.66N/AN/AN/A
GENB
GENERATE BIOMEDICINES INC
N/AN/AN/A-81.40%N/A-0.232.85100.00%-782.40%-632.91%
BMEA
BIOMEA FUSION INC
$88.21M-243.70%-102.20%-130.18%-4,616.90%0.985.23N/AN/AN/A
GMAB
GENMAB A
$16.77B17.40%11.70%12.87%45.20%1.202.0293.60%25.90%39.60%
FLNA
FILANA THERAPEUTICS INC
$89.37M-97.90%-69.40%-122.08%613.30%0.592.23N/AN/AN/A
SRPT
SAREPTA THERAPEUTICS INC
$2.50B-57.50%-20.40%-31.15%-21.20%1.942.3261.80%-32.50%-31.94%
CNTA
CENTESSA PHARMACEUTICALS PLC
$3.79B-67.70%-47.50%-54.43%-51.00%0.4910.57100.00%-1,618.00%-1,521.18%
PYPD
POLYPID LTD
$78.10M-366.30%-143.80%-229.81%-391.20%1.031.97N/AN/AN/A
CRMD
CORMEDIX INC
$522.52M58.50%33.00%23.44%91.90%1.042.1188.50%52.30%49.02%
GERN
GERON CORP
$1.01B-33.30%-14.80%-11.08%-7.80%1.534.6697.40%-45.40%-27.65%
TVRD
TVARDI THERAPEUTICS INC
$30.86M-115.90%-33.70%-31.65%-30.90%0.403.48100.00%-346.50%-220.05%
MLYS
MINERALYS THERAPEUTICS INC
$2.03B-32.90%-31.70%-23.91%-50.70%0.0243.76N/AN/AN/A
MANE
VERADERMICS INC
N/AN/AN/AN/AN/A-0.063.29N/AN/AN/A
VTVT
VTV THERAPEUTICS INC
$150.85M-74.10%-43.50%-32.39%481.60%0.4013.54N/AN/AN/A
AVXL
ANAVEX LIFE SCIENCES CORP
$253.92M-38.80%-35.00%-31.54%408.90%0.0520.87N/AN/AN/A
ZLAB
ZAI LAB LTD
$2.02B-22.80%-15.00%-22.91%-131.50%0.642.4558.50%-38.10%-37.65%
SION
SIONNA THERAPEUTICS INC
$1.67B-22.90%-21.70%-23.95%-26.20%0.0620.61N/AN/AN/A
NAUT
NAUTILUS BIOTECHNOLOGY INC
$494.87M-33.60%-28.30%-32.21%-29.10%0.2213.33N/AN/AN/A
VSTM
VERASTEM INC
$447.08M-1,849.90%-111.50%-119.61%-421.20%3.313.0982.90%-677.60%-673.91%
KPTI
KARYOPHARM THERAPEUTICS INC
$95.57MN/A-179.30%-917.99%-86.00%-1.371.1295.90%-134.20%-102.79%
CVM
CEL SCI CORP
$29.86M-226.10%-102.20%-130.17%-116.00%1.061.40N/AN/AN/A
GLSI
GREENWICH LIFESCIENCES INC
$360.08M-1,042.80%-565.50%-891.35%1,235.40%0.742.35N/AN/AN/A
ABVX
ABIVAX SA
$8.69B-147.50%-88.30%-41.91%-845.00%0.288.75100.00%-7,354.50%-4,781.42%
INBX
INHIBRX BIOSCIENCES INC
$970.78M-269.60%-71.90%-113.47%-137.00%17.333.93100.00%-10,773.50%-9,835.15%
IMRX
IMMUNEERING CORP
$343.95M-43.30%-39.70%-25.25%-222.20%0.0617.50N/AN/AN/A
CHRS
COHERUS ONCOLOGY INC
$265.31M789.40%42.40%150.08%287.40%3.231.4767.20%398.40%419.77%
EQ
EQUILLIUM INC
$125.44M-148.80%-109.40%-76.58%1,073.10%0.1210.85100.00%-555.90%-547.72%
TLSA
TIZIANA LIFE SCIENCES LTD
$150.47M-250.50%-101.10%-425.46%-666.20%1.871.02N/AN/AN/A
IOVA
IOVANCE BIOTHERAPEUTICS INC
$1.54B-54.50%-42.40%-50.73%-98.90%0.313.2034.30%-148.40%-149.16%
MBX
MBX BIOSCIENCES INC
$1.38B-28.70%-27.60%-23.53%-41.10%0.0424.62N/AN/AN/A
ENLV
ENLIVEX LTD
$29.15M-62.90%-53.30%-82.65%-29,748.70%0.206.43N/AN/AN/A
PTCT
PTC THERAPEUTICS INC
$5.53B-362.40%25.20%43.97%88.70%-15.122.3597.30%39.40%49.05%
FATE
FATE THERAPEUTICS INC
$141.84M-55.00%-38.10%-48.19%-38.40%0.545.79100.00%-2,051.10%-2,051.08%

Biotech Stocks FAQ

What are the best biotech stocks to buy right now in Mar 2026?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best biotechnology stocks to buy right now are:

1. Veracyte (NASDAQ:VCYT)


Veracyte (NASDAQ:VCYT) is the #1 top biotech stock out of 605 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Veracyte (NASDAQ:VCYT) is: Value: B, Growth: A, Momentum: C, Sentiment: A, Safety: B, Financials: B, and AI: C.

Veracyte (NASDAQ:VCYT) has a Due Diligence Score of 59, which is 34 points higher than the biotech industry average of 25.

VCYT passed 19 out of 33 due diligence checks and has strong fundamentals. Veracyte has seen its stock lose -2.67% over the past year, overperforming other biotech stocks by 32 percentage points.

Veracyte has an average 1 year price target of $45.17, an upside of 37.75% from Veracyte's current stock price of $32.79.

Veracyte stock has a consensus Buy recommendation according to Wall Street analysts. Of the 6 analysts covering Veracyte, 50% have issued a Strong Buy rating, 16.67% have issued a Buy, 16.67% have issued a hold, while 0% have issued a Sell rating, and 16.67% have issued a Strong Sell.

2. Pharming Group Nv (NASDAQ:PHAR)


Pharming Group Nv (NASDAQ:PHAR) is the #2 top biotech stock out of 605 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Pharming Group Nv (NASDAQ:PHAR) is: Value: B, Growth: B, Momentum: B, Sentiment: B, Safety: C, Financials: B, and AI: C.

Pharming Group Nv (NASDAQ:PHAR) has a Due Diligence Score of 30, which is 5 points higher than the biotech industry average of 25.

PHAR passed 9 out of 33 due diligence checks and has average fundamentals. Pharming Group Nv has seen its stock return 86.1% over the past year, overperforming other biotech stocks by 121 percentage points.

Pharming Group Nv has an average 1 year price target of $39.00, an upside of 140.3% from Pharming Group Nv's current stock price of $16.23.

Pharming Group Nv stock has a consensus Buy recommendation according to Wall Street analysts. Of the 2 analysts covering Pharming Group Nv, 0% have issued a Strong Buy rating, 100% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Jazz Pharmaceuticals (NASDAQ:JAZZ)


Jazz Pharmaceuticals (NASDAQ:JAZZ) is the #3 top biotech stock out of 605 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Jazz Pharmaceuticals (NASDAQ:JAZZ) is: Value: B, Growth: A, Momentum: C, Sentiment: C, Safety: C, Financials: B, and AI: B.

Jazz Pharmaceuticals (NASDAQ:JAZZ) has a Due Diligence Score of 16, which is -9 points lower than the biotech industry average of 25. Although this number is below the industry average, our proven quant model rates JAZZ as a "A".

JAZZ passed 5 out of 33 due diligence checks and has weak fundamentals. Jazz Pharmaceuticals has seen its stock return 39.8% over the past year, overperforming other biotech stocks by 74 percentage points.

Jazz Pharmaceuticals has an average 1 year price target of $223.91, an upside of 18.42% from Jazz Pharmaceuticals's current stock price of $189.08.

Jazz Pharmaceuticals stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 11 analysts covering Jazz Pharmaceuticals, 63.64% have issued a Strong Buy rating, 27.27% have issued a Buy, 9.09% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the biotech stocks with highest dividends?

Out of 6 biotech stocks that have issued dividends in the past year, the 3 biotech stocks with the highest dividend yields are:

1. Novabay Pharmaceuticals (NYSEMKT:NBY)


Novabay Pharmaceuticals (NYSEMKT:NBY) has an annual dividend yield of 281.69%, which is 242 percentage points higher than the biotech industry average of 39.49%.

Novabay Pharmaceuticals's dividend payout ratio of -105.3% indicates that its high dividend yield might not be sustainable for the long-term.

2. Dominari Holdings (NASDAQ:DOMH)


Dominari Holdings (NASDAQ:DOMH) has an annual dividend yield of 21.04%, which is -18 percentage points lower than the biotech industry average of 39.49%.

Dominari Holdings's dividend payout ratio of 8.4% indicates that its high dividend yield is sustainable for the long-term.

3. Oramed Pharmaceuticals (NASDAQ:ORMP)


Oramed Pharmaceuticals (NASDAQ:ORMP) has an annual dividend yield of 7.14%, which is -32 percentage points lower than the biotech industry average of 39.49%.

Oramed Pharmaceuticals's dividend payout ratio of 0% indicates that its high dividend yield might not be sustainable for the long-term.

Why are biotech stocks up?

Biotech stocks were up 2.92% in the last day, and up 1.12% over the last week. Sarepta Therapeutics was the among the top gainers in the biotechnology industry, gaining 34.98% yesterday.

Sarepta Therapeutics shares are trading higher after the company announced that early results from Phase 1/2 studies of SRP-1001 for facioscapulohumeral muscular dystrophy type 1 and SRP-1003 for myotonic dystrophy type 1. Also, the company generated proof-of-concept data for SRP-1001 and SRP-1003.

What are the most undervalued biotech stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued biotech stocks right now are:

1. Harmony Biosciences Holdings (NASDAQ:HRMY)


Harmony Biosciences Holdings (NASDAQ:HRMY) is the most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Harmony Biosciences Holdings has a valuation score of 71, which is 56 points higher than the biotech industry average of 15. It passed 5 out of 7 valuation due diligence checks.

Harmony Biosciences Holdings's stock has dropped -16.37% in the past year. It has overperformed other stocks in the biotech industry by 18 percentage points.

2. Incyte (NASDAQ:INCY)


Incyte (NASDAQ:INCY) is the second most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Incyte has a valuation score of 71, which is 56 points higher than the biotech industry average of 15. It passed 5 out of 7 valuation due diligence checks.

Incyte's stock has gained 48.57% in the past year. It has overperformed other stocks in the biotech industry by 83 percentage points.

3. Exelixis (NASDAQ:EXEL)


Exelixis (NASDAQ:EXEL) is the third most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Exelixis has a valuation score of 43, which is 28 points higher than the biotech industry average of 15. It passed 3 out of 7 valuation due diligence checks.

Exelixis's stock has gained 13.46% in the past year. It has overperformed other stocks in the biotech industry by 48 percentage points.

Are biotech stocks a good buy now?

63.68% of biotech stocks rated by analysts are a strong buy right now. On average, analysts expect biotech stocks to rise by 67.6% over the next year.

2.4% of biotech stocks have a Zen Rating of A (Strong Buy), 4.37% of biotech stocks are rated B (Buy), 47.38% are rated C (Hold), 34.28% are rated D (Sell), and 11.57% are rated F (Strong Sell).

What is the average p/e ratio of the biotechnology industry?

The average P/E ratio of the biotechnology industry is 25.57x.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.